These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20400728)

  • 1. Bias associated with failing to incorporate dependence on event history in Markov models.
    Bentley TG; Kuntz KM; Ringel JS
    Med Decis Making; 2010; 30(6):651-60. PubMed ID: 20400728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of categorizing continuous variables in decision-analytic models.
    Bentley TG; Weinstein MC; Kuntz KM
    Med Decis Making; 2009; 29(5):549-56. PubMed ID: 19596867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Noon KM; Montgomery SM; Adlard NE; Kroes MA
    J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism.
    Monahan M; Ensor J; Moore D; Fitzmaurice D; Jowett S
    J Thromb Haemost; 2017 Aug; 15(8):1591-1600. PubMed ID: 28520199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for the prevention of recurrent erysipelas and cellulitis.
    Dalal A; Eskin-Schwartz M; Mimouni D; Ray S; Days W; Hodak E; Leibovici L; Paul M
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009758. PubMed ID: 28631307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis.
    Choi SE; Brandeau ML; Basu S
    BMJ Open; 2017 Nov; 7(11):e018374. PubMed ID: 29146652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes.
    Vemer P; Al MJ; Oppe M; Rutten-van Mölken MP
    Pharmacoeconomics; 2013 Aug; 31(8):719-30. PubMed ID: 23736971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Is the Effect of Using a Competing-risks Estimator when Predicting Survivorship After Joint Arthroplasty: A Comparison of Approaches to Survivorship Estimation in a Large Registry.
    Cuthbert AR; Graves SE; Giles LC; Glonek G; Pratt N
    Clin Orthop Relat Res; 2021 Feb; 479(2):392-403. PubMed ID: 33105301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-state models: a review.
    Hougaard P
    Lifetime Data Anal; 1999 Sep; 5(3):239-64. PubMed ID: 10518372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio.
    Alarid-Escudero F; Kuntz KM
    Pharmacoeconomics; 2020 Mar; 38(3):285-296. PubMed ID: 31755032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Decision Model Suggests Total Shoulder Arthroplasty is Superior to Hemiarthroplasty in Young Patients with End-stage Shoulder Arthritis.
    Bhat SB; Lazarus M; Getz C; Williams GR; Namdari S
    Clin Orthop Relat Res; 2016 Nov; 474(11):2482-2492. PubMed ID: 27457626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cohort decomposition for Markov cost-effectiveness models.
    Hazen G; Li Z
    Med Decis Making; 2011; 31(1):19-34. PubMed ID: 20530723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
    Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
    Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.
    Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Wanner C; Fellström B; Gray A; Landray MJ; Baigent C; Mihaylova B;
    Heart; 2017 Dec; 103(23):1880-1890. PubMed ID: 28780579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and testing of a health economic Markov model for treatment of anorexia nervosa.
    Svendsen VG; Lokkerbol J; Danner UN; Jansingh A; Evers SM; Wijnen BF
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1243-1251. PubMed ID: 36047856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.